In this regard, evidence from different clinical trials demonstrates that inhibition of the sodium glucose co-transporter 2 (SGLT2) results in decreased cardiovascular events and CVD-related mortality in both patients with and without diabetes [11–13]. The gene discussed is SLC5A2; the disease is diabetes mellitus.